These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33892178)

  • 1. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody.
    Morrell AE; Robinson ST; Ke HZ; Holdsworth G; Guo XE
    Bone; 2021 Aug; 149():115967. PubMed ID: 33892178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?
    Sapir-Koren R; Livshits G
    Osteoporos Int; 2014 Dec; 25(12):2685-700. PubMed ID: 25030653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
    Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
    Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck.
    Power J; Doube M; van Bezooijen RL; Loveridge N; Reeve J
    Bone; 2012 May; 50(5):1107-14. PubMed ID: 22353552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture.
    Power J; Poole KE; van Bezooijen R; Doube M; Caballero-Alías AM; Lowik C; Papapoulos S; Reeve J; Loveridge N
    J Bone Miner Res; 2010 Aug; 25(8):1867-76. PubMed ID: 20200987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
    Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
    J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered.
    Moustafa A; Sugiyama T; Prasad J; Zaman G; Gross TS; Lanyon LE; Price JS
    Osteoporos Int; 2012 Apr; 23(4):1225-34. PubMed ID: 21573880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size.
    Kogawa M; Khalid KA; Wijenayaka AR; Ormsby RT; Evdokiou A; Anderson PH; Findlay DM; Atkins GJ
    Am J Physiol Cell Physiol; 2018 Jan; 314(1):C53-C61. PubMed ID: 28978523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein.
    Gould NR; Williams KM; Joca HC; Torre OM; Lyons JS; Leser JM; Srikanth MP; Hughes M; Khairallah RJ; Feldman RA; Ward CW; Stains JP
    Elife; 2021 Mar; 10():. PubMed ID: 33779549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
    Front Immunol; 2018; 9():2467. PubMed ID: 30410490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
    Robling AG; Niziolek PJ; Baldridge LA; Condon KW; Allen MR; Alam I; Mantila SM; Gluhak-Heinrich J; Bellido TM; Harris SE; Turner CH
    J Biol Chem; 2008 Feb; 283(9):5866-75. PubMed ID: 18089564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.
    Spatz JM; Wein MN; Gooi JH; Qu Y; Garr JL; Liu S; Barry KJ; Uda Y; Lai F; Dedic C; Balcells-Camps M; Kronenberg HM; Babij P; Pajevic PD
    J Biol Chem; 2015 Jul; 290(27):16744-58. PubMed ID: 25953900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
    Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
    Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
    Allison H; Holdsworth G; McNamara LM
    BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of osteocyte function and the emerging importance of sclerostin.
    Compton JT; Lee FY
    J Bone Joint Surg Am; 2014 Oct; 96(19):1659-68. PubMed ID: 25274791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization.
    Lewis KJ; Choi RB; Pemberton EZ; Bullock WA; Firulli AB; Robling AG
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31505764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
    Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
    PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.